Netflix can sustain its lofty valuation only if global subscriber growth can support increasing content spending and debt.Technologyread more
Under CEO James Gorman, Morgan Stanley has emphasized its wealth management division, a far steadier business than its trading operations.Financeread more
China has other "weapons" in its trade battle with the United States — and selling off its U.S. Treasury holdings will not be one of them, said Richard McGregor, senior fellow...China Economyread more
Treasury Secretary Steven Mnuchin said a call between U.S. and China trade officials is scheduled for later on Thursday.Marketsread more
Three candidates calling for a mixed approach also co-sponsored Sen. Bernie Sanders' 'Medicare for All' bill.2020 Electionsread more
Here are the biggest calls on Wall Street on ThursdayInvestingread more
Raymond James upgraded Apple and said its most recent checks show Apple is preparing to bring a 5G iPhone to a wider range of models than previously thought.Marketsread more
Barr and Ross had defied Democrats' subpoenas for information about the Trump administration's efforts to add a citizenship question to the 2020 census.Politicsread more
IBM's year-over-year revenue has now declined for four quarters in a row. Impact from Red Hat is not yet factored into the company's guidance.Technologyread more
Diagnostics company Theranos has cut back use of its key finger-prick technology to just one lab test after pressure from regulators, The Wall Street Journal reported, citing a person familiar with the matter.
That followed a recent unannounced visit from Food and Drug Administration inspectors due to concerns about data the company had submitted to the agency to win approval for its testing methods, the person said, according to the WSJ report late Thursday. Theranos has submitted approval requests for almost 130 tests. The Journal reported that the FDA has approved just one, for herpes.
Theranos didn't immediately respond to an emailed request for comment sent outside of regular office hours.
Theranos has been a Silicon Valley darling after developing a finger-prick blood-testing technology that competes with the traditional use of arm-drawn blood. It was valued at as much at $9 billion in its most recent round of fundraising
The company's founder, Elizabeth Holmes, told CNBC earlier Thursday that Theranos' "nanotainers" for collecting finger-pricked blood were only used for FDA-cleared assays.
Holmes' comments to CNBC followed an an earlier report by the Journal that cited several former Theranos employees as saying that the company may have exaggerated the accuracy of lab tests conducted on its own machines, and that Theranos largely used blood-testing equipment bought by external suppliers, not its own technology.
The Journal reported that David Boies, Theranos' outside lawyer, and Heather King, Theranos' general counsel, both denied the claims. King added the company has been "upfront and transparent with regulators" about its procedures.
Theranos later said in a statement that the initial Journal report was "factually and scientifically erroneous and grounded in baseless assertions by inexperienced and disgruntled former employees and industry incumbents."
The company said it sent more than 1,000 pages of documentation to the Journal to demonstrate the tests' accuracy and refute the allegations.
The Journal reported that Theranos declined to allow the newspaper to visit the company's offices to view its technology; Holmes told CNBC that the company had offered to come to the Journal's offices to demonstrate its technology.
A Journal spokesperson later told CNBC the newspaper "fully stands by [writer] John Carreyrou's article about Theranos, which was richly sourced and thoroughly researched."
—Abigail Stevenson and Fred Imbert contributed to this report.